PlumX Metrics
Embed PlumX Metrics

LTBR acts as a novel immune checkpoint of tumor-associated macrophages for lung adenocarcinoma immunotherapy

2023
  • 0
    Citations
  • 79
    Usage
  • 0
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Dataset Description

Background: Tumor-associated macrophages (TAMs) has been reported to mediate the resistance of LUAD patients to ICI therapy. However, its underlying mechanisms and whether TAMs could be promising targets to overcome the non-response after ICI application remain to be unveiled. Methods: Immune multi-omics analysis was implemented with a large clinical cohort encompassing 1045 LUAD cases to screen out potential immune checkpoints. scRNA-seq analysis revealed their distribution in LUAD immune cells. The key molecule and related mechanisms were investigated in vitro and in vivo. Clinical verification in ICI therapy cohorts and TAMs-targeted delivery system had been performed for further clinical translation. Findings: LTBR, as a potential immune checkpoint, was screened out. Its high expression, duplication and low methylation were corelated with LUAD unfavorable survival. scRNA-seq and FACS analysis showed the highest expression of LTBR in TAMs. Moreover, TAM-targeted inhibition of LTΒ...

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know